Newamsterdam Pharma (NAMS) traded down -8.67 % during a 24 hours period ending at 03:55 PM Central Europe on Monday 26th. One Newamsterdam Pharma stock can currently be bought for about USD 19.34 on popular exchanges. Current supply of Newamsterdam Pharma stocks is 119.5 mn. Newamsterdam Pharma has a current market capitalization of USD 2.4 bn and approximately USD 45.6 mn worth of Newamsterdam Pharma was traded on exchanges in the last 24 hours. Since last month end, Newamsterdam Pharma has traded -13.32 % down. Simple moving average of last 200 days is at USD 30.13. The highest price of past 52 weeks was recorded at USD 42.2 on 05/11/2026. 52 weeks low was at USD 19.13 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
Redcare Pharmacy (RDC.DE) traded down -0.7 % and now trades at EUR 77.8. Redcare Pharmacy has a market capitalisation of EUR 1.6 bn.
Pharvaris (9EN.F) traded up 2.76 % and now trades at EUR 28.1. Current market capitalisation for Pharvaris is EUR 2 bn.
Basic-fit (BFIT.AS) traded down -1.1 % and now trades at EUR 30.12. Basic-fit has a market capitalisation of EUR 1.9 bn. Basic-fit has a current price to earnings ratio of 40.63.
Uniqure (UQ1.F) traded up 3.76 % and now trades at EUR 19.7. Current market capitalisation for Uniqure is EUR 1.4 bn.
Corbion (CRBN.AS) traded down -0.97 % and now trades at EUR 25.38. Corbion has a market capitalisation of EUR 1.4 bn. Current price/earnings ratio for Corbion is 23.05.
About Newamsterdam Pharma
The NewAmsterdam Pharma Co NV is a late-stage clinical biopharmaceutical company based in Naarden, the Netherlands. The company specializes in the development of oral small molecule therapies for cardiovascular and other metabolic diseases. These therapies are intended for patients residing in the United States and Europe. You can find more information about their operations and offerings on their website, which is www.newamsterdampharma.com . The company’s stock is traded on the Nasdaq stock exchange.
